Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 18/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16104531 | 0.88 | GABRA5 (0.52) | GABRA5ITGA5 | |
| SCHEMBL2689395 | 0.87 | GABRA5 (0.64) | GABRA5 | |
| SCHEMBL2689011 | 0.87 | MAPT (0.49) | GABRA5MAPTL3MBTL1 | |
| SCHEMBL6370913 | 0.86 | GABRA5 (0.49) | GABRA5ITGA5 | |
| SCHEMBL2689121 | 0.85 | GABRA5 (0.45) | GABRA5ITGA5 | |
| SCHEMBL2687932 | 0.85 | GABRA5 (0.63) | GABRA5ITGA5 | |
| SCHEMBL2688726 | 0.84 | GABRA5 (0.60) | GABRA5MAPTL3MBTL1 | |
| SCHEMBL2688362 | 0.84 | ITGA5 (0.42) | GABRA5ITGA5L3MBTL1 | |
| SCHEMBL2688688 | 0.84 | GABRA5 (0.51) | GABRA5ITGA5 | |
| SCHEMBL4562218 | 0.82 | GRM5 (0.42) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | GABRA5, GABRA3, GABRA1 | GABRA5 1/4885MAPT 2518/4885ITGA5 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.